Expert Interviews

Managing Diabetes in a 68-Year-Old Patient: Benefits of Follow-Up and Combination Therapy
August 23, 2024

Continuing the discussion on a 68-year-old patient, the panel discusses the importance of follow-up and the benefits of combination therapies in older adults.

Assessing a 68-Year-Old Patient with Symptoms of Diabetes and Unintentional Weight Loss
August 23, 2024

Focusing on diabetes testing and treatment practices, Conan Tu, MD, MBA, DACD, BC-ADM, presents the profile of a 68-year-old new patient who presents with symptoms in line with a family history of type 2 diabetes.

Managing Diabetes and Hypertension in an 84-Year-Old Widow: Addressing Medication Burden and Glycemic Control Challenges
August 23, 2024

Conan Tu, MD, MBA, DACD, BC-ADM, presents a case of an 84-year-old patient with diabetes experiencing medication burden and glycemic control challenges.

Recognizing Aging and Adapting Care While Managing Diabetes in Various Environments
August 23, 2024

Experts on diabetes define the concept of homeostenosis and describe the importance of recognizing signs of aging and adapting care to fit the needs of older adult patients.

Tailoring Diabetes Care and Gauging Physician Knowledge on Treatment Strategies for Older vs Younger Adults
August 23, 2024

Medha Munshi, MD, and Conan Tu, MD, MBA, DACD, BC-ADM, begin a discussion on geriatric diabetes care by providing an overview of the condition and gauging physician knowledge with polling questions.

Effectiveness of Anti-Obesity Drugs for CVD Prevention: A Clinician Discussion
August 21, 2024

Anila Chadha, MD, talks to Patient Care about how antiobesity medications can aid in reducing CVD risk in patients with obesity.

Cardiovascular Disease Prevention in Patients with Obesity: An Expert Perspective
August 19, 2024

Anila Chadha, MD, highlights key preventive strategies to reduce CVD risk in patients with obesity and how to tailor them to address individual patient needs.

The CAHtalyst Adult Phase 3 Clinical Trial of Crinecerfont: Principal Investigator Interview
August 19, 2024

More than 6 in 10 adults treated with the investigational CRF1 antagonist crinecerfont reached a physiologic glucocorticoid dose with androstenedione control maintained.

The Ideal Treatment for CAH? We Asked the Expert
August 19, 2024

Dr Richard Auchus says the ideal treatment for congenital adrenal hyperplasia is a long way off but describes a "block and replace" strategy that holds great promise.

Crinecerfont Could Help Improve Physical, Emotional Health for Individuals with CAH
August 16, 2024

Crinecerfont, a CRF1 antagonist, could help reduce glucocorticoid doses for individuals with CAH and improve physical and emotional quality of life, says leading researcher.